Major grant from UK for global stroke study INTERACT3
Researchers in China were awarded joint funding from four major United Kingdom agencies, the Medical Research Council (MRC), National Institute for Health Research (NIHR), Department of International Development (DIFID) and Wellcome Trust, for a clinical trial to improve the management of acute intracerebral haemorrhage in low and middle-income countries.
A total of 2 million pounds was secured to complete the ongoing INTERACT3 (INTEnsive care bundle with blood pressure reduction in Acute Cerebral hemorrhage Trial) study which is operated by Heart Health Research Center, and academically guided by The George Institute China. The study uses a novel, stepped wedge, cluster clinical trial design, and is being rolled out as a quality improvement strategy across hospitals in China and overseas.
Cardiovascular disease, including stroke, is a leading killer-disease, threatening the health and wellbeing of millions of Chinese people. China has a particular high share of the global burden of stroke because of the large ‘high-risk’ population. Acute spontaneous non-traumatic intracerebral hemorrhage (ICH), or bleeding from a ruptured blood vessel within the brain, is the most serious and difficult-to-treat type of stroke. How best to manage various physiological abnormalities, such as elevated blood pressure and glucose (‘sugar’) in the blood, of patients with ICH is a hot topic at home and abroad.
Dr. Lily Song, Head of stroke at The George Institute China and key researcher of the INTERACT3 said, “We hope the study will provide important further evidence to support guidelines and clinical practice, not just in China where the burden of stroke is enormous, but all around the world.”
Professor Craig Anderson, Executive Director of The George Institute China and the study’s principal investigator, said “Research funding from prestigious and competitive bodies is quite significant and will enable researchers to play a critical role in effectively targeting the leading causes of disease burden worldwide. We are privileged to have a role in this effort.”